Financhill
Buy
54

SMMNY Quote, Financials, Valuation and Earnings

Last price:
$26.75
Seasonality move :
-3.21%
Day range:
$26.67 - $26.89
52-week range:
$23.28 - $30.19
Dividend yield:
3.73%
P/E ratio:
26.87x
P/S ratio:
2.43x
P/B ratio:
2.98x
Volume:
15.9K
Avg. volume:
64.4K
1-year change:
-10.47%
Market cap:
$60.2B
Revenue:
$24.3B
EPS (TTM):
$1.00

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Siemens Healthineers AG has -- downside to fair value with a price target of -- per share.

SMMNY vs. S&P 500

  • Over the past 5 trading days, Siemens Healthineers AG has underperformed the S&P 500 by -1.37% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Siemens Healthineers AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Siemens Healthineers AG has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Siemens Healthineers AG reported revenues of $6.2B.

Earnings Growth

  • Siemens Healthineers AG has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Siemens Healthineers AG reported earnings per share of $0.25.
Enterprise value:
57.3B
EV / Invested capital:
--
Price / LTM sales:
2.43x
EV / EBIT:
16.38x
EV / Revenue:
2.31x
PEG ratio (5yr expected):
2.19x
EV / Free cash flow:
19.23x
Price / Operating cash flow:
20.23x
Enterprise value / EBITDA:
11.92x
Gross Profit (TTM):
$9.6B
Return On Assets:
4.45%
Net Income Margin (TTM):
9.03%
Return On Equity:
11.11%
Return On Invested Capital:
10.84%
Operating Margin:
14.28%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $22.5B $23.7B $24.9B $5.9B $6.2B
Gross Profit $8B $8.9B $9.6B $2.2B $2.4B
Operating Income $2.3B $2.8B $3.4B $639.8M $888.1M
EBITDA $3.9B $4.4B $4.8B $1.1B $1.2B
Diluted EPS $0.69 $0.89 $1.00 $0.21 $0.25
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $25.4B $13.1B $14.2B $15.4B $15.8B
Total Assets $43.1B $49.1B $49.4B $50B $50.8B
Current Liabilities $9.8B $13.4B $15B $11.7B $14.4B
Total Liabilities $25.8B $30.2B $30.5B $29.9B $30.5B
Total Equity $17.3B $18.9B $18.9B $20.2B $20.3B
Total Debt $572.1M $759M $51.3M $723.5M $120.1M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $2.4B $2.1B $3.8B $314.1M $400.1M
Cash From Investing -$943.7M -$1.1B -$954.2M -$219.5M -$195.9M
Cash From Financing -$779.7M -$888.5M -$2.7B $185.2M -$570.3M
Free Cash Flow $1.5B $1.3B $3B $132.6M $197.2M
SMMNY
Sector
Market Cap
$60.2B
$34.5M
Price % of 52-Week High
88.97%
49.05%
Dividend Yield
3.73%
0%
Shareholder Yield
1.86%
-1.01%
1-Year Price Total Return
-10.47%
-35.15%
Beta (5-Year)
1.001
0.615
Dividend yield:
3.73%
Annualized payout:
$0.51
Payout ratio:
101.31%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $27.46
200-day SMA
Sell
Level $27.29
Bollinger Bands (100)
Sell
Level 25.82 - 28.24
Chaikin Money Flow
Buy
Level 98.9K
20-day SMA
Sell
Level $27.15
Relative Strength Index (RSI14)
Sell
Level 46.38
ADX Line
Sell
Level 17.37
Williams %R
Buy
Level -85.9578
50-day SMA
Sell
Level $26.94
MACD (12, 26)
Buy
Level 6.74
25-day Aroon Oscillator
Buy
Level 56
On Balance Volume
Neutral
Level 51.6K

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.1167)
Sell
CA Score (Annual)
Level (-0.4848)
Buy
Beneish M-Score (Annual)
Level (-2.4859)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.8013)
Buy
Piotroski F Score (Annual)
Level (8)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (10)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2024) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (17% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (20%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. Americas represents 42% of total sales, Europe, Middle East, and Africa 33%, and Asia-Pacific including China the remainder.

Stock Forecast FAQ

In the current month, SMMNY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SMMNY average analyst price target in the past 3 months is --.

  • Where Will Siemens Healthineers AG Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Siemens Healthineers AG share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Siemens Healthineers AG?

    Analysts are divided on their view about Siemens Healthineers AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Siemens Healthineers AG is a Sell and believe this share price will rise from its current level to --.

  • What Is Siemens Healthineers AG's Price Target?

    The price target for Siemens Healthineers AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SMMNY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Siemens Healthineers AG is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of SMMNY?

    You can purchase shares of Siemens Healthineers AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Siemens Healthineers AG shares.

  • What Is The Siemens Healthineers AG Share Price Today?

    Siemens Healthineers AG was last trading at $26.75 per share. This represents the most recent stock quote for Siemens Healthineers AG. Yesterday, Siemens Healthineers AG closed at $26.86 per share.

  • How To Buy Siemens Healthineers AG Stock Online?

    In order to purchase Siemens Healthineers AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock